The impact of PARPs and ADP-ribosylation on inflammation and host–pathogen interactions

Anthony R. Fehr,1 Sasha A. Singh,2 Catherine M. Kerr,1 Shin Mukai,2 Hideyuki Higashi,2 and Masanori Aikawa2,3,4

1Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas 66045, USA; 2Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA; 3Center for Excellence in Vascular Biology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA; 4Department of Human Pathology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health, Moscow 119146, Russian Federation

Poly-adenosine diphosphate-ribose polymerases (PARPs) promote ADP-ribosylation, a highly conserved, fundamental posttranslational modification (PTM). PARP catalytic domains transfer the ADP-ribose moiety from NAD+ to amino acid residues of target proteins, leading to mono- or poly-ADP-ribosylation (MARylation or PARylation). This PTM regulates various key biological and pathological processes. In this review, we focus on the roles of the PARP family members in inflammation and host–pathogen interactions. Here we give an overview the current understanding of the mechanisms by which PARPs promote or suppress proinflammatory activation of macrophages, and various roles PARPs play in virus infections. We also demonstrate how innovative technologies, such as proteomics and systems biology, help to advance this research field and describe unanswered questions.

Polyadenosine diphosphate-ribose polymerases (PARPs) promote ADP-ribosylation, one of the fundamental posttranslational modifications (PTMs) [Gupte et al. 2017]. This ubiquitous PTM regulates various key biological and pathological processes, including DNA repair, cell differentiation, gene transcription, signal transduction pathways, energy metabolism, and epigenetics. PARP catalytic domains transfer the ADP-ribose moiety from NAD+ to amino acid residues of target proteins, leading to mono- or poly-ADP-ribosylation (MARylation or PARylation). PARP members thus function as “writers” of ADP-ribose. Among the 17 human PARPs, PARP1, PARP2, PARP5A, and PARP5B promote PARylation, while most other members (e.g., PARP3, PARP4, PARP6, PARP14, and PARP15) catalyze MARylation [Hottiger 2015; Ryu et al. 2015; Gupte et al. 2017]. A new nomenclature has thus been proposed to call them the diphtheria toxin-like ADP-ribosyltransferases [ARTDts], e.g., ARTD1 for PARP1 [Hottiger et al. 2010]. Differences between each PARP lead to diverse functions for PARPs in biological processes such as the innate immune response [Fig. 1].

PARP family members contain a few structural domains, in addition to the catalytic domain. One of such domains is the macrodomain that is contained in PARP9, PARP14, and PARP15, for which they are called “macro” PARPs. Macromdomains bind to, and in some cases hydrolyze, ADP-ribose in the free or protein-bound form (“readers” of ADP-ribosylation) and influence many biological processes [Rack et al. 2016]. Evidence has linked the MacroPARPs PARP9 and PARP14 in multiple types of cancers, particularly lymphomas (Aguir et al. 2000, Cho et al. 2009). PARP14 may also play an important role in cell morphology [Vyš et al. 2013]. We found the interplay of PARP9 and PARP14 in the regulation of macrophage activation [Iwata et al. 2016], as described in this review.

Different cellular distributions of PARPs may also indicate their distinctive targets and functions [Vyš et al. 2013]. While PARP1 is only found in the nucleus, PARP6, PARP8, PARP12, PARP13, PARP15, and PARP16 are mostly located in the cytoplasm. PARP2, PARP3, PARP4, PARP5A, PARP5B, PARP7, PARP9, PARP10, PARP11, and PARP14 are seen in both the nucleus and cytoplasm.

ADP-riborylation is reversed by “erasers” such as poly-ADP-ribose glycohydrolase [PARG], ADP-ribosylhydrolase 3 (ARH3), and macromdomains such as Mdo2 [Miwa and Sugimura 1971; Oka et al. 2006; Jankevicius et al.

© 2020 Fehr et al. This article, published in Genes & Development, is available under a Creative Commons License [Attribution 4.0 International], as described at http://creativecommons.org/licenses/by/4.0/.
PARG is a potent enzyme that degrades poly-ADP-ribose, with several isoforms that are derived from the single PARG gene through alternative splicing (i.e., 110-, 102-, 99-, and 60-kDa proteins). The 110-kDa isoform, mostly seen in the nucleus, appears to play a dominant role in the PAR degradation. PARG cannot erase ADP-ribose when bound to proteins and leaves MARylated amino acid residues. PARG is a useful tool that enables researchers the ability to enrich for MARylated peptides for mass spectrometry analysis of ADP-ribosylation (Higashi et al. 2019).

PARPS in immune cells: a focus on inflammation

Immune cells serve an important role in the immune system and differentiate into various subsets that perform a spectrum of unique functions. The balance of the number of different immune cell types and their activation levels is crucial for health and disease. Overwhelming evidence has associated chronic inflammation with various pathological conditions and their potential causes, including atherosclerosis, cardiovascular events, cancer, autoimmune diseases, metabolic disorders, neurological diseases, and aging (Johnston et al. 1987; Gisterå and Hansson 2017; Tabas and Lichtman 2017; Decano and Aikawa 2018; Funes et al. 2018; Swirski and Nahrendorf 2018; O'Rourke et al. 2019). Various signal-transduction pathways participate in macrophage activation, which are often regulated by PTMs such as phosphorylation and acetylation (Tietzel and Mosser 2002; Park et al. 2011; Zhou et al. 2014; Nakano et al. 2016; Vergadi et al. 2017; Dean et al. 2019). This section focuses on the impact of PARPs and ADP-ribosylation in macrophage activation and also summarizes their roles in the biology of other immune cells.

PARP1 induces macrophage activation and inflammation

Evidence suggests that ADP-ribosylation participates in inflammation (Bai and Virág 2012; Rosado et al. 2013; Kunze and Hottiger 2019). PARP1 has been implicated in the mechanisms for responses (e.g., proinflammatory cytokine expression) of macrophages or macrophage-like cell lines to pathogen-associated molecular patterns [PAMPs], including lipopolysaccharide [LPS] (Hassa et al. 2005; Liu et al. 2012a; Yang et al. 2014; Minotti et al. 2015; Bohio et al. 2019). Some responses involve the interplay between PARP1 and nuclear factor κB [NF-κB], a key...
The role of nicotinamide adenine dinucleotide (NAD+) in PARP1-mediated macrophage activation

PARPs catalyze the transfer of ADP-ribose from NAD+ to target proteins. Hence, NAD+ is consumed by PARPs, and the activity of PARPs depends on the availability of NAD+ (Gupte et al. 2017). A recent report indicates that cell-autonomous production of NAD+ via the kynurenine pathway (KP) is required to induce normal inflammatory macrophage activation and that the de novo NAD+ synthesis can be impaired in aged macrophages (Minhas et al. 2019). Another study proposed a mechanism linking the NAD+ salvage pathway to LPS-induced PARP1 consumption of NAD+ (Cameron et al. 2019). In LPS-stimulated macrophages, an increase in reactive oxygen species induces DNA damage, which in turn activates PARP1, leading to a reduction of available NAD+. Nicotinamide phosphoribosyltransferase (NAMPT) is therefore increased to maintain NAD+ levels, which is crucial for normal inflammatory macrophage activation.

PARP1 participates in the biology of other immune cells

PARP1 modulates the differentiation of T cells into effector T cells such as T helper 1 (Th1), T helper 2 (Th2), and regulatory T cells (Tregs) (Saenz et al. 2008; Nasta et al. 2010). PARP1 deficiency in murine T cells leads to the increased expression of the Th1 cytokine interferon-γ (IFN-γ) and the decreased production of the Th2 cytokine interleukin 4 (IL-4) (Saenz et al. 2008). IL-4 suppresses IFNγ secretion and Th1 differentiation, and PARP1 promotes IL-4 expression via chromatin modifications at the IL-4 locus (Saenz et al. 2008). Although PARP1 is not involved in the differentiation of naïve T cells into T helper 17 (Th17) cells, it does impact Tregs, as these cells are augmented in multiple organs in PARP1-deficient mice (Nasta et al. 2010). Using PARP1-deficient mice, Nasta et al. (2010) demonstrated that PARP1 suppresses the expression of Foxp3 and thus generation of Tregs via modulation of the chromatin structure and/or regulation of the transcription factors. Additional studies used PARP1-deficient mice further demonstrated mechanisms for PARP1-regulated suppression of Tregs via transforming growth factor β (TGF β) receptors (Zhang et al. 2013). Recent reports demonstrate the interactive role of PARP1 and PARP2 in maintaining the number and function of T cells and promoting the development and function of B cells (Navarro et al. 2017; Galindo-Campos et al. 2019). Defective thymocyte maturation is observed in PARP1/PARP2-deficient mice, and accordingly T-cell numbers in peripheral blood are reduced (Galindo-Campos et al. 2019). In PARP1/PARP2-deficient mice, the development of bone marrow B cells is impaired, leading to the reduction of transitional and follicular B cells (Navarro et al. 2017). PARP1 also plays a role in the maturation and function of dendritic cells by regulating the production of IL-10 and IL-12 (Aldinucci et al. 2007).

PARP1 promotes experimental cardiovascular disorders


PARP9 and PARP14 regulate macrophage activation

While many reports suggested multiple proinflammatory roles for PARP1, contributions of other PARP family members in macrophage activation remain incompletely understood. We demonstrated that PARP9 and PARP14 coregulate proinflammatory activation of human macrophages (Iwata et al. 2016). In this study we took a systems-biology approach involving unbiased proteomics, bioinformatics, and network analysis to identify potential molecular switches of the balance of proinflammatory versus non/anti-inflammatory macrophage phenotypes as potential therapeutic targets. We performed proteomics of human and mouse macrophage-like cell lines...
treated with IFNγ or IL-4, which represent so-called proinflammatory M1 versus non/anti-inflammatory M2 cells. We processed our proteomics data of >5000 proteins with a conventional filtering method as well as our original clustering method [Ricchiuto et al. 2015] to identify molecules that increased with IFNγ and decreased with IL-4 [Iwata et al. 2016]. Interestingly, the only protein that emerged from this stringent criteria was PARP14. We also recognized that PARP9 showed similar responses.

The same study demonstrated in vitro that PARP14 suppresses proinflammatory IFNγ–STAT1 signaling and activates the anti-inflammatory IL-4–STAT6 pathway in primary human macrophages [Fig. 2; Iwata et al. 2016]. Silencing of PARP14 by siRNA accelerated the induction of proinflammatory cytokines and chemokines [e.g., TNFa, IL-1β, and CCL2/MCP-1] in IFNγ-treated macrophages and suppressed anti-inflammatory molecules [e.g., MRC1 and Arg1] in IL-4-treated cells. PARP9 silencing generally exerted opposing effects. PARP9 also appeared to interfere with PARP14’s suppressive action on the IFNγ–STAT1 axis, thus promoting proinflammatory macrophage activation [Fig. 2]. Cell-free enzyme reactions with mass spectrometry as a read-out further indicated that ADP-ribosylation of STAT1 by PARP14 may reduce phosphorylation of this proinflammatory mediator. However, the mechanisms used by PARP14 to interact with STAT1 and influence its ADP-ribosylation and phosphorylation requires further investigations.

Due to the well-recognized knowledge that targets identified in basic science often fail in the clinical stage, we performed network analysis that closely linked the network of PARP9, PARP14, and their first neighbor interactors with the human coronary artery disease gene module [Fig. 3]. As predicted, in vivo studies in Parp14−/− mice demonstrated that PARP14 participates in the pathogenesis of arterial diseases. Consistent with in vitro studies, PARP14 deficiency indeed mitigated lesion development and inflammatory burden in models of coronary artery disease in mice [Iwata et al. 2016].

The anti-inflammatory role of PARP14 reported by us are consistent with other reports. Iqbal et al. [2014] demonstrated in macrophages that PARP14 reduces mRNA stability and thus expression levels of tissue factor, a surface glycoprotein that plays a major thrombogenic role in macrophage-rich atherosclerotic lesions. PARP14’s association with anti-inflammatory STAT6 was first described using a yeast two-hybrid screen [Goenka and Boothby 2006]. Although subsequent studies were not done in the context of macrophage activation, they indicated that PARP14’s enhancement of IL-4–STAT6’s transcriptional activity may be more relevant to its promoter-binding functions rather than its potential to ADP-ribosylate STAT6 itself [Fig. 2; Goenka et al. 2007; Mehrotra et al. 2011]. For instance, PARP14 can act as a transcriptional repressor of STAT6 target genes, but activation by IL-4 leads to its aut ribosylation and dissociation of PARP14 from a DNA-protein complex, thereby promoting STAT6 binding instead [Fig. 2; Goenka et al. 2007; Mehrotra et al. 2011]. Thus, despite the accumulating evidence that PARP14 promotes an anti-inflammatory state, there does not yet exist enough information to disentangle PARP14’s enzymatic functions from that of its protein-interaction functions, and how each of these functions may maintain an anti-inflammatory response, irrespective of the cytokine or stimulus.

Evidence established that macrophages are a heterogeneous group of cells, as represented by the well-known theory of M1 versus M2 polarization. Recent understanding, however, suggests that macrophage heterogeneity is more complex and multidimensional than the M1/M2 dichotomy [Murray et al. 2014; Nahrendorf and Swirski 2016; Decano and Aikawa 2018]. In our study, single-cell analysis demonstrated that IFNγ-elicited macrophages remain largely heterogeneous, consisting of a few clusters rather than uniformly “polarized” toward an activated phenotype [Iwata et al. 2016]. Gene similarity maps demonstrated close interactions between PARP9, PARP14, STAT1, and STAT6, supporting our in vitro data described above.

**PARP14 regulates lymphocyte biology**

Several pieces of evidence demonstrate that PARP14 promotes the differentiation of naïve T cells into Th2 cells by responding to IL-4. PARP14 is thought to become enzymatically active and dissociate from the promoter(s), thereby allowing phosphorylated STAT6 to bind and activate target genes [Mehrotra et al. 2011]. A green question mark indicates that the fate of ADP-ribosylated substrates is not known. The IFNγ and IL-4 mechanisms appear distinct, but they may be partial and complementary pictures of a complex biology.

**Figure 2.** A partial model of PARP14 and PARP9 function in macrophage activation. In vivo and in vitro studies pertaining to IFNg signaling in primarily macrophages suggest that PARP14 mitigates proinflammatory phosphorylated STAT1 via ADP-ribosylation, and that PARP9 may act to inhibit PARP14’s enzymatic activity [Iwata et al. 2016]. In vitro studies pertaining to IL-4 signaling in the context of B-cell biology suggest that in nonstimulating conditions PARP14 is a suppressor of STAT6 target genes. In response to IL-4, PARP14 is thought to become enzymatically active and dissociate from the
regulating STAT6-dependent Gata3 expression and that PARP14-deficient mice show reduced symptoms of allergic airway disease [Mehrotra et al. 2013; Riley et al. 2013]. PARP14 enhances STAT3-dependent Th17 differentiation [Mehrotra et al. 2015]. PARP14 is also implicated in immunoglobulin class switching in B cells by enhancing the IL-4 and STAT6 signal, which produces the IgE isotype, a major factor in allergic hypersensitivity [Mehrotra et al. 2011].

Other PARPs in macrophage biology

As discussed, while several studies have reported how PARP1, PARP2, PARP9, and PARP14 promote or suppress macrophage activation via signaling pathways [e.g. NF-κB, IFNγ–STAT1, and IL-4–STAT6], the evidence remains scant on the roles that other PARPs play in macrophage biology. LPS increases the mRNA expression of PARP3, PARP4, PARP7, PARP8, PARP10, PARP11, PARP12, and PARP13 in murine bone marrow-derived macrophages, but there are no known functions for these PARPs in macrophage biology [Caprara et al. 2018]. Other reports have linked PARP10 and PARP12 with NF-κB signaling [Verheugd et al. 2013; Welsby et al. 2014]. Although these lines of evidence may suggest roles of PARPs other than PARP1, PARP2, PARP9, and PARP14 in macrophage biology, more investigations are needed to better understand how these PARPs participate in macrophage activation and inflammatory diseases.

PARPs in cancer immunology

PARPs have been targets for drug development, particularly in the cancer field. The most active targets include PARP1, and more recently PARP14 [Berger et al. 2018; Qin et al. 2019]. Studies that used the small molecule inhibitors demonstrated that PARP suppression reduces proinflammatory responses or enhances anti-inflammatory functions of macrophages [Haskó et al. 2002; Wang et al. 2013; Shrestha et al. 2016; Dharwal et al. 2019]. Recent work showed that PARP inhibition in combination with PD-1/PD-L1 blockade could be effective for BRCA1-deficient tumors by activating antigen presenting cells such as dendritic cells via the cGAS-STING pathway [Jiao et al. 2017; Ding et al. 2018; Dunphy et al. 2018]. Major effects reported in these studies may reflect PARP1 suppression. These inhibitors, however, are not strictly specific for PARP1 and their effects on other PARP members and targets other than PARPs thus need to be addressed [Wahlberg et al. 2012].

Activated macrophages link ADP-ribosylation with protein homeostasis

A global view of PARP activity on immunity undoubtedly requires proteomics. However, even with the most advanced mass spectrometry technologies available, disentangling the unique and overlapping functions of PARPs remains very challenging. Only a handful of
studies have begun to interrogate the complex biology of the PARP family members in the context of immunity. Nearly 30 years ago, radioactive labeling strategies demonstrated an increase in ADP-ribosylation signal in human monocyte-derived macrophages in response to IFNγ [Bertron et al. 1991]. In addition, there was no increase in PARP1 mRNA, implicating additional mechanisms rather than an increase in total PARP1 levels for the increase in ADP-ribosylation. Using quantitative proteomics, we made a similar observation in IFNγ-treated THP-1 and RAW264.7 macrophage-like cell lines [Iwata et al. 2016]. Moreover, PARP14 and PARP9 exhibited the increased expression following IFNγ exposure and had the opposite response to IL-4, decreasing in abundance over the stimulation period. These contrasting proinflammatory and anti-inflammatory responses by PARP9 and PARP14 were distinct from the other PARPs measured in the study.

More specifically, their responses to IFNγ were characteristic of known cytokine inducible genes, STAT1, NMI [IN-myel interactor], OAS2, IFIH1, and IFTT3, among several others. This study thus provided a plausible scenario where the increase in global ADP-ribosylation in macrophages could be mediated in part by PARP14 [Iwata et al. 2016].

In a separate study, using quantitative proteomics in combination with shRNA-mediated knockdown experiments, PARP14 interactors were pursued in the context of LPS signaling in RAW264.7 cells [Caprara et al. 2018]. A PARP14 coimmunoprecipitation of these RAW264.7 cells after LPS treatment found that SQSTM1 (Sequestome-1), a receptor linking autophagy and ubiquitylation, PARP9, DTX3L, and NMI were immunoprecipitated with a PARP14 antibody specifically in PARP14 wild-type but not PARP14 knockdown cells, indicating that these proteins form a PARP14–protein interaction network in response to LPS.

Protein–protein interactions alone do not clarify the role of PARP enzyme activities in immunity. To date, only one study has investigated ADP-ribosylated substrates in immune cells on a global level [Higashi et al. 2019]. Since ADP-ribosylome studies are technically challenging to perform, they rely on specialized proteomic workflows to enrich and sequence ADP-ribosylated proteins. These findings were not surprising since this protein class is highly abundant, and thereby more conducive to identifying ADP-ribosylated peptides. Other ADP-ribosylated proteins were associated with pathways involved in neutrophil degranulation and activation, IL-12 signaling, and glycolysis. Moreover, ADP-ribosylation of a subset of the ribosome/RNA-binding proteins increased in response to IFNγ, as did ADP-ribosylated forms of PARP14 and PARP9, and interestingly SQSTM1, the ubiquitin pathway associated protein identified as a candidate PARP14 binding partner [Caprara et al. 2018]. These studies point toward ADP-ribosylation linking macrophage activation with protein homeostasis, as indicated by the changes in ADP-ribosylation in numerous translational machinery, and by the emergence of proteins involved in ubiquitination [Higashi et al. 2019].

**PARP14 is involved in host–pathogen interactions**

ADP-ribosylation is well-known to play an important role in many host–pathogen interactions. For instance, many important bacterial toxins are ADP-ribosyltransferases [ARTs]. Bacterial pathogens such as *B. pertussis, V. cholera*, *P. aeruginosa*, *C. botulinum*, *S. aureus*, and *E. coli* encode for ARTs that target proteins such as elongation factor 2, actin, and Rho GTPases that lead to cell death [Holbourn et al. 2006]. As discussed above, mammals also encode for a diverse set of ARTs, most of which are termed PARPs, that impact infections. Here we discuss mammalian encoded PARPs that are involved in host–pathogen interactions, focusing on virus infections.

**Mammalian PARPs display several properties indicative of involvement in host–pathogen interactions**

PARP14 interacts with pathogens in many ways, and here we describe specific cases where they either promote or restrict virus replication and the innate immune response. This discussion is summarized in Table 1 and Figure 1. However, we start by discussing characteristics that indicate an important role for PARPs in the host response to infection.

First, many mammalian PARPs are stimulated by the production of IFN [IFN-stimulated genes [ISGs]], and thus are part of the mammalian antiviral defense system [Atasheva et al. 2012; Zhang et al. 2015; Ecke et al. 2017; Li et al. 2018; Grunewald et al. 2019a]. Also, several mono-ADP-ribosylating PARPs are rapidly evolving, indicating ongoing conflict with pathogens. The PARP domain of PARP13, a disordered region of PARP4, and the macrodomain[s] of the three macro-PARPs, PARP9, PARP14, and PARP15, are all under positive selection [Kerns et al. 2008; Daugherty et al. 2014]. Furthermore, Parp14 and Parp15 have undergone multiple rounds of gene loss and duplication, which creates novel gene products needed for continual adaptation to new pathogens.

Several PARP proteins are also present in stress granules, which are important membrane-less organelles that function to restrict the translation of RNA when cells are under stress, such as during a virus infection. They are often characterized by the presence of TIA1, TIAR, and G3BP1, but are known to contain several hundred proteins [McCormick and Khaperskyy 2017]. Interestingly, several proteins in stress granules are ADP-ribosylated, and PARPs, including 5a, 12, 13, 14, and 15, are known
Some virus families encode for a macrodomain protein that reverses cellular ADP-ribosylation

Several decades ago, a conserved domain was identified in all coronaviruses [CoVs], togaviruses, and hepatitis E virus.
that was termed the “X” domain (Gorbalenya et al. 1991; Koonin et al. 1992). These domains are structurally homologous to the nonhistone part of the macroH2A protein and are now known as macrodomains (Allen et al. 2003). Macrodomains from all three viral families bind mono- and poly-ADP-ribose, and can efficiently remove mono-ADP-ribose from proteins by hydrolysis, strongly indicating a role for ADP-ribosylation in either promoting or inhibiting the replication of these viruses (Egloff et al. 2006; Li et al. 2016). Several studies on the CoV and alphavirus macrodomains have established that this protein domain is critical for either replication or pathogenesis (Eriksson et al. 2008; Park and Griffin 2009; Fehr et al. 2015, 2016; McPherson et al. 2017). Recent studies using chikungunya virus (CHIKV) macrodomain mutants showed that macrodomain ADP-ribose binding facilitated initiation of virus replication, while hydrolase activity was essential for the amplification of replication complexes (Abraham et al. 2018). Infection with ADP-ribosylhydrolase (ARH)-deficient CoVs, including severe acute respiratory syndrome (SARS)-CoV and murine hepatitis virus (MHV), led to higher levels of IFN and other cytokines, indicating that they may block the innate immune response (Fehr et al. 2016; Grunewald et al. 2019a). The ARH-deficient MHV replicates poorly in primary macrophages, and importantly, this defect could be partially rescued by PARP inhibitors, directly indicating PARPs in the antiviral response to CoVs (Grunewald et al. 2019a). However, it remains unknown what proteins may be targeted by the viral macrodomains (for reviews, see Fehr et al. 2018; Leung et al. 2018).

The roles of PARP1 and the Tankyrase PARPs in virus replication.

Some of the first reports of PARPs and ADP-ribosylation impacting virus infection focused on the role of PARP1 on retrovirus and HIV-1 integration and replication. Gäken et al. (1996) first demonstrated that PARP inhibitors led to reduced retroviral integration into host chromatin. They further used antisense oligonucleotides and overexpression of dominant-negative PARP1 to confirm that PARP activity is required for integration of retroviral vectors. Other groups further demonstrated the importance of PARP activity in retrovirus and HIV-1 integration into host chromosomes using siRNA transfected and PARP1-deficient cells (Ha et al. 2001; Kameoka et al. 2005). Mechanistically, it was suggested that PARP1 may help resolve a 4- to 6-bp gap in the genome produced during integration (Ha et al. 2001). PARP1 activity may also impact HIV-1 transcription and replication (Kameoka et al. 1999, 2004). However, these results have been confounded by other reports that demonstrated either no evidence that PARP1 was required for efficient HIV-1 integration or replication (Baekelandt et al. 2000; Ariumi et al. 2005), or evidence that PARP1 can repress HIV-1 or retrovirus infection (Parent et al. 2005; Bueno et al. 2013). Bueno et al. (2013) found that PARP1 inhibited retroviral infection in a chicken B lymphoblastoid cell line, while Parent et al. (2005) showed that PARP1 could bind to the transactivation response element (TAR) and inhibit HIV-1 transcription by competing with TAR for binding to p-TEF2b. The impact of PARP1 on HIV-1 infection remains controversial and is likely context-dependent.

In addition to its role in regulating retrovirus replication, PARylation enhances and represses several other viruses. This includes herpesviruses, where PARPs have a wide range of effects. PARP1 and the tankyrase PARP5a modify the EBV protein EBNA1. PARylation of EBNA1 causes it to dissociate from the dyad symmetry elements, which restricts OriP binding and impairs the maintenance of the viral episome during latency (Deng et al. 2005; Tempora et al. 2010). PARP1 also binds to the TR sequences in KSHV, which leads to reduced viral genome levels during latency. PARP1 and the Ste-20-like kinase hKFC synergistically bind to and ADP-ribosylate/phosphorylate the γ-2 herpesvirus replication and transcription activator protein (RTA) [Fig. 4A]. These interactions suppress RTA-mediated transcriptional activation and KSHV lytic reactivation (Gwack et al. 2003). Two mechanisms have been described by which γ-herpesviruses counter PARP1 activity. First, it was found that ORF49 of γHV-68 binds to PARP1, preventing it from interacting with RTA [Fig. 4B]. In addition, the processivity factor of KSHV and γHV-68, PF-8, binds to and targets PARP1 for degradation, which reduces PARylated RTA and enhances virus replication [Fig. 4C; Noh et al. 2012, Chung et al. 2015]. In contrast to the antiviral effects of PARPs during γ-herpesvirus infection, PARP activity seems to promote the replication

Figure 4. Mechanisms used by herpesviruses to affect PARylation and their impact on replication. [A] PARP-1 can bind to and ADP-ribosylate the γHV RTA, which inhibits its ability to initiate lytic replication. [B] The γHV-68 protein ORF49 binds to PARP1 and prevents it from interacting with and ADP-ribosylating RTA, which allows RTA to initiate viral gene transcription. [C] The KSHV and γHV-68 PF-8 proteins bind to PARP1 and target it for ubiquitination and degradation. This again prevents ADP-ribosylation of RTA, which allows it to initiate lytic replication. [D] The HSV-1 ICP0 protein targets PARG for ubiquitination and degradation, resulting in enhanced PARylation during infection and increased replication. (ADPr) ADP-ribose; (Ub) ubiquitin.
of HSV-1, the prototype α-herpesvirus. PARP5a (Tankyr-
ase-1) expression was increased and it was translocated
to the nucleus during HSV-1 infection. Knockdown of
both PARP5a and PARP5b resulted in a threefold to four-
fold decrease in virus replication, and inhibition of their
catalytic activity with XAV-939 resulted in a greater
than 1-log reduction in virus replication (Li et al. 2012).
To further indicate that PARP activity is important for vi-
rus replication, HSV-1 infection significantly increased
PARylation. The ICP0 protein targets nuclear forms of
PARP glycohydrolase (PARG), the enzyme that degrades
PAR, for ubiquitination and degradation, providing a pos-
sible mechanism for the dramatic increase in PARylation
during infection (Fig. 4D; Grady et al. 2012).

Finally, poly-ADP-ribosylation is implicated as having
prooviral activities in several viral systems. PARP inhib-
itors have led to greatly reduced infectivity of adenoviru-
es, possibly through the ADP-ribosylation of their core
proteins [Déry et al. 1986]. PARP inhibitors also inhibit
JC virus replication (Nukuzuma et al. 2013). PARP1 binds
to the porcine reproductive and respiratory syndrome vi-
rus (PRRSV) nucleocapsid protein, and again, PARP inhi-
bitors restricted the replication of PRRSV in cell culture
(Liu et al. 2015b). The nucleocapsid protein of the related
coronaviruses is also ADP-ribosylated, however the im-
 pact of this modification on virus replication or pathogen-
esis remains unknown (Grunewald et al. 2018). Last,
PARP activity is required for efficient activity of the
RNA polymerases derived from multiple strains of influ-
 enza virus, indicating a potential proviral role for ADP-
ribosylation during influenza infection (Bortz et al.
2011). In summary, PARylation has a variety of different
functions that can both repress and enhance virus
replication.

The roles of nonenzymatic and mono-ADP-
ribosylating PARPs in virus replication
and the antiviral response.

Nonenzymatic and mono-ADP-ribosylating PARPs have
a variety of roles in promoting or inhibiting virus replica-
tion. This class of PARPs include the zinc finger [ZnF] PARPs
(7, 12, and 13), the macrodomain-containing PARPs
(9, 14, and 15), and several PARPs that do not fit
into a specific category (4, 6, 8, 10, and 11). Here, we dis-
cuss what is known about each of these PARPs in the in-
nate immune response to viruses.

CCCH ZnF PARPs

ZnF PARPs contain one or more ZnF domains. These do-
 mains are small protein motifs that enable these PARPs to
bind RNA. All three ZnF PARPs use this domain to inter-
act with viral RNA and inhibit either translation or
degrade viral RNA, though the specific RNA sequence
that each PARP binds to is likely unique. In addition, all
three ZnF PARPs use either the enzymatic or nonenzym-
atic functions in their PARP domain to impact the in-
nate immune response or virus replication.

PARP13 (ZnF antiviral protein) PARP13, or ZnF antivi-
r al protein [ZAP], was one of the first PARPs identified to
have antiviral activities when, in a screen for antiviral
ISGs, it was found to potently inhibit murine leukemia vi-
rus [MLV] replication (Gao et al. 2002). Somewhat surpris-
ingly, ZAP lacks the triad motif [H-Y-E] needed for
catalytic activity and has no auto-ADP-ribosylating activity
[Kleine et al. 2008]. As such, most of its antiviral
activity is independent of ADP-ribosylation. Since its dis-
covery, ZAP has been shown to inhibit the replication of
several viral families, including retroviruses, alphaviruses,
filoviruses, picornaviruses, herpesviruses, arteriviruses,
orthomyxoviruses, flaviviruses, and hepatitis B virus
[Bick et al. 2003; Muller et al. 2007; Zhu et al. 2011;
Xuan et al. 2013; Li et al. 2015, 2015a; Chiu et al. 2018;
Xie et al. 2018; Zhao et al. 2019]. ZAP is transcribed into four
different isoforms, with ZAPL and ZAPS being the most
studied [Li et al. 2019]. ZAPL contains the inactive PARP
catalytic activity and has no auto-ADP-ribosylating
domain, while ZAPS does not. ZAPL tends to
have greater antiviral activity, and this may be due, at
least in part, to prenylation of the PARP domain
[Charron et al. 2013; Schwerk et al. 2019]. In addition to the PARP
domain, ZAP contains four ZnF-binding domains and a
single WWE domain. ZAP uses its ZnF-binding domains
to bind to viral RNA and recruits both the poly(A)-specific
ribonuclease [PARN] and the RNA exosome to degrade the
viral RNA (Guo et al. 2007). It also inhibits translation by
blocking the interaction between eIF4G and eIF4A, and its
ability to block translation is required for it to degrade
RNA. In addition, ZAP antiviral activity is enhanced by
the ubiquitin ligase activity of TRIM25. TRIM25 binds to
ZAP and ubiquitinates unknown proteins to enhance the
antiviral activity of ZAP [Li et al. 2017; Zheng et al.
2017].

ZAP targets HIV RNAs for degradation, and prefers to
target CG dinucleotides [Takata et al. 2017]. Consistent
with this, an HIV-1 mutant with an increased CG content
replicated very poorly in MT4 cells, but that replication
was restored in ZAP-deficient cells. In addition, ZAP tar-
gets the 3′ UTR of Japanese encephalitis virus [JEV], which
contains a high CG content [Chiu et al. 2018]. Interest-
ingly, it appears many viruses maintain a low CG dinucleo-
tide level, and the level of ZAP sensitivity of several
viruses mildly correlates with their CG dinucleotide con-
tent [Takata et al. 2017]. However, ZAP sensitivity of a
panel of alphaviruses does not correlate with the CG dinu-
cleotide content found in their genome or individual viral
genes, suggesting that the CG dinucleotide motif is not
the only determinant for ZAP recognition [Li et al.
2019]. The localization of ZAP to stress granules also ap-
ppears to be functionally important for its antiviral activity
against alphaviruses, as ZAP mutants that do not localiz-
to SGs are unable to block SINV replication [Law et al.
2019]. In vivo, Zap knockout [Zc3hav1−/−] mice showed
enhanced replication of SINV in 10-d-old mice as expected
[Kozaki et al. 2015]. Though surprisingly, in 23-d-old
weaning pups it was shown that a neurovirulent strain of
SINV can use ZAP to decrease its replication in initially
infected cells in vivo such that it prevents immune
recognition, allowing the virus to spread to the central nervous system (CNS) and promote disease (Wang et al. 2016).

In addition, different studies have found conflicting results regarding the ability of ZAP to impact the innate immune response. It was originally found that ZAPS, but not ZAPL, potentiates RIG-I-dependent type I interferon (IFN-I) production in human cells by binding to RIG-I via its ZnF domains and promoting its oligomerization (Fig. 1A; Hayakawa et al. 2011; Chiu et al. 2018). However, ZAP does not appear to enhance RIG-I-dependent IFN-I production in mouse cells (Lee et al. 2013). More recent data indicate that ZAPS may also reduce IFN mRNA by binding to the 3′ UTR of IFN mRNA and targeting it for degradation (Fig. 1A; Schwerk et al. 2019). It is conceivable that ZAP-S uses both functions but in a context-dependent manner.

While ZAPL does not contain an active PARP domain, in some cases it is required for the ADP-ribosylation of proteins. For instance, the C terminus of ZAPL binds to the influenza virus polymerase proteins PB2 and PA, which causes their subsequent poly-ADP-ribosylation, ubiquitination, and degradation [Liu et al. 2015a]. It is unknown which PARP and E3 ubiquitin ligase mediates these effects. Knockdown of ZAPL modestly increased influenza virus replication in cell culture, though it is not clear whether this is due to its ability to bind and target PB2 and PA for degradation. Interestingly, this ZAPL activity was countered by the PB1 protein, which bound to ZAPL preventing the ubiquitination of PB2 and PA, demonstrating that the virus has evolved ways to neutralize the antiviral activity of ZAP [Fig. 5A]. In addition to PB1, several other viral proteins have been found to counter ZAP using multiple mechanisms (Fig. 5B–D). Influenza A NS1 prevents ZAP-S from binding to its target RNA [Tang et al. 2017], γHV-68 RTA disrupts the intermolecular interaction of ZAP [Xuan et al. 2013], HSV-1 UL41 degrades ZAP mRNA [Su et al. 2015], and, finally, the enterovirus (EV)-71 3C protease cleaves ZAP protein [Xie et al. 2018]. Due to its broad-spectrum antiviral activity, it is likely there are even more viral proteins that function to counter ZAP.

**PARP12**

PARP12 is a mono-ADP-ribosyltransferase and has four or five N-terminal CCCH-type zinc finger (ZnF) domains that are important for RNA binding, one or two WWE domains in the middle of the protein, which are important for ADP-ribosyl binding, and a PARP domain at the C terminus, which provides the protein with mono-ADP-ribosylating activity (Welsby et al. 2014). There are two splice forms of PARP12 mRNA, PARP12L, and PARP12S (Atasheva et al. 2012). PARP12L contains both the ZnF domains and the PARP catalytic domain, while PARP12S has the ZnF domains but lacks the PARP catalytic domain.

As described above, PARP12 translocates to cytoplasmic stress granules upon cell stress (Leung et al. 2011; Welsby et al. 2014). PARP12 initially localizes to the trans-Golgi network (TGN) and translocates to stress granules during stress stimuli in several different cell types. This activity has been linked to the ZnF domains, as mutations in the ZnF domains abrogated the ability of PARP12 to move to stress granules [Welsby et al. 2014]. The translocation of PARP12 may also depend on PARP1 acting as a stress sensor in the nucleus, as an increase in unconjugated PAR is a key factor that promotes the recruitment of PARP12 to stress granules [Catara et al. 2017]. The translocation of PARP12 to stress granules is reversible, as it relocates back to the Golgi once the stress is relieved.

The antiviral role of PARP12 was first described in an overexpression screen, where it mildly inhibited the replication of both VSV and MHV-68 [Liu et al. 2012b]. Shortly after this, another study found that PARP12 was differentially expressed in cells that cleared VEEV replication compared with those that were persistently infected [Atasheva et al. 2012]. Further analysis showed that PARP12L, but not PARP12S, expression from a VEEV replicon or virus restricts VEEV replication, as well as several other viruses including Sindbis virus (SINV), encephalomyocarditis virus (EMCV), vesicular stomatitis virus (VSV), Rift Valley fever virus (RVFV), and chikungunya virus (CHIKV). Subsequently, this group showed that PARP12 strongly inhibited both cellular and viral translation [Atasheva et al. 2014]. Immunoprecipitation with PARP12 identified several ribosomal proteins and translation and elongation factors, indicating that PARP12 interacts with ribosomes. Interestingly, PARP12 required its enzymatic activity to block translation, but not to inhibit virus

---

**Figure 5.** Viral mechanisms of ZAP antagonism. (A) IAV protein PB1 binds to ZAP, which prevents its interaction with the PA and PB2 proteins that otherwise would lead to PARylation, ubiquitination, and degradation of these proteins. (B) IAV NS1 and γHV-68 RTA proteins interact with ZAP, preventing its association with viral RNA. (C) The EV-71 3C protease cleaves ZAP to prevent it from accumulating. (D) HSV-1 UL41 protein cleaves ZAP mRNA to prevent its translation. (ADPr) ADP-ribose; (Ub) ubiquitin.
replication, indicating that PARP12 may use distinct mechanisms to block virus replication and cellular translation.

Additionally, PARP12 was identified in a screen for ISGs that inhibit Zika virus (ZIKV) [Li et al. 2018]. Using both knockout cells and overexpression, the authors showed that PARP12 was both necessary and sufficient for the inhibition of ZIKV replication. PARP12 was required for the ADP-ribosylation, ubiquitination, and subsequent degradation of ZIKV NS1 and NS3 proteins. This activity did not require either the ZnF or WVE domains of PARP, but did require its catalytic domain, as an inactive catalytic domain reversed the regulatory effects of PARP12 on viral protein degradation. Interestingly, NS1 and NS3 appeared to be poly-ADP-ribosylated, indicating that PARP12 may work with another PARP to mediate the poly-ADP-ribosylation of these proteins. PARP12 also has a role in the restriction of coronavirus (CoV) replication, as siRNA knockdown of PARP12 partially restored replication of MHV lacking the ADP-ribosylhydrolase (ARH) activity of the CoV macrodomain [Grunewald et al. 2019a]. The mechanism used by PARP12 to restrict MHV replication remains unknown. Finally, PARP12 was also shown to enhance NF-κB signaling, possibly by interacting with TRIF [Fig. 1A; Welsby et al. 2014].

PARP7 (TiPARP) PARP7, also known as tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly-ADP-ribose polymerase (TiPARP), has a single ZnF domain that mediates RNA binding. It also has a WVE domain and a PARP catalytic domain capable of mono-ADP-ribosylation [Kozaki et al. 2017].

Like PARP12, TiPARP was also shown to block VEEV replication and inhibit cellular translation when transfected into cells by a VEEV replicon [Atasheva et al. 2014]. In a separate study, siRNA knockdown of TiPARP in U373 human astrocyte cells led to increased replication of SINV and rubella virus replication [Kozaki et al. 2017]. The increase in SINV replication was also demonstrated in TiParp<−/− mice. TiPARP-mediated inhibition of SINV was dependent on its ZnF domain, which binds to SINV RNA and recruits RNA degradation factors to sites of viral replication. This suggests that TiPARP recognizes specific virus RNAs for degradation, however the target specificity of TiPARP is still unknown.

TiPARP also has proviral effects in addition to its antiviral functions. TiPARP negatively regulates the type I IFN response by ADP-ribosylating TBK1 [Fig. 1A; Yamada et al. 2016]. The ADP-ribosylation of the kinase domain of TBK1 suppresses IFN production. It was suggested that negative regulation of IFN production by TiPARP may help protect the cell from the harmful effects of type I IFN. The same study found that the loss of TiPARP led to decreased IAV replication, which strongly correlated with increased IFN-I production. Our group has also found that siRNA knockdown of TiPARP led to decreased replication of MHV and increased IFN-I production, further indicating TiPARP as a proviral factor for some viruses [Grunewald et al. 2019a,b]. However, it remains unclear whether the ability of TiPARP to enhance MHV or IAV replication is tied to its ability to block the IFN-I response.

Macromdomain-containing PARPs

The macro PARPs contain two (PARP9/PARP15) or three (PARP14) macrodomains that mediate binding to ADP-ribose, as described above. While some macrodomains can cleave ADP-ribose from a substrate, it is likely that macrodomains within these PARP proteins only bind ADP-ribose. All three macro PARPs are rapidly evolving [Daugherty et al. 2014], and PARP15 has been identified in stress granules [Leung et al. 2011]; however, direct evidence of their involvement in virus infections is limited. No study has identified a role for PARP15 in modulating virus infection or the innate immune response, and thus it will not be discussed further.

PARP9 (BAL1) PARP9 was originally termed B-aggressive lymphoma 1 gene (BAL1) as it was identified as a risk factor for large diffuse B-cell lymphomas [Aguir et al. 2005]. It is catalytically inactive, at least when expressed by itself, but can ADP-ribosylate ubiquitin in the presence of an E3 ubiquitin ligase, DTX3L [Yang et al. 2017]. As described above, PARP9 promotes STAT1 phosphorylation, proinflammatory gene expression, and differentiation into M1-like macrophages [Iwata et al. 2016]. In the antiviral response, PARP9 expression in malignant B-cell lymphoma lines can lead to widespread induction of ISG expression [Juszczynski et al. 2006]. Zhang et al. [2015] found that the complex of PARP9 and DTX3L attached to STAT1 to mediate the hyper-responsive nature of a mutant STAT1 protein (STAT1-CC). The PARP9–DTX3L complex ubiquititates histone proteins, most notably H2B, which led to chromatin remodeling and enhanced expression of at least a subset of ISGs [Fig. 1B]. This interaction was necessary and sufficient to inhibit the replication of multiple viruses, including EMCV, IAV, and SINV. The PARP9–DTX3L complex also ubiquititates the EMCV 3C protease, which leads to its degradation, but this effect was mostly, if not completely, due to DTX3L activity.

PARP14 (CoaST-6) PARP14 was originally identified as Collaborator of STAT6 (CoaST6) [Goenka and Boothby 2006]. It has a range of effects on cell physiology and immunity that were largely anti-inflammatory [Cho et al. 2011, 2013; Barbarulo et al. 2013; Vyas et al. 2013; Iansante et al. 2015; Iwata et al. 2016; Krishnamurthy and Kaplan 2016]. In the antiviral response, PARP14 instead is required to enhance IFN-I production in RAW cells [transformed peritoneal macrophages] following LPS treatment [Caprara et al. 2018], in primary macrophage cells during CoV infection, and following treatment of human A549 cells with poly[dI:dC] [Grunewald et al. 2019a]. Following LPS treatment, PARP14-deficient cells showed similar levels of IRF-3 phosphorylation and nuclear translocation, but had reduced levels of Pol II recruited to the promoters of IRF-3-dependent genes [Caprara et al. 2018]. There was also a dramatic reduction in H3K27
acetylation, a known marker of active promoters and enhancers [Fig. 1A]. It is unclear whether this function of PARP14 is dependent on its catalytic activity. It is also not yet known whether PARP14 has the same function in the cellular response to virus infection or poly(I:C). These two studies also found that PARP14 was required to restrict the replication of *S. typhimurium* and an ARH-deficient MHV, though it is not known whether the ability of PARP14 to inhibit these pathogens is tied to its role in up-regulating IFN production or whether these are distinct functions of PARP14. It is important to note that these experiments were done with undifferentiated or M0 macrophages, while other studies where PARP-14 was found to have anti-inflammatory functions used M1 or M2 macrophages, differentiated by further IFN-γ or IL-4 treatment. This suggests that PARP14 function is likely context-dependent.

**Other PARPs**

The final class of PARPs do not fit into any of the other defined classes of PARPs, have no similar domains other than the PARP domain, and are thus simply termed “other PARPs.” These PARPs include PARPs 4, 6, 8, 10, 11, and 16. PARP6 and PARP8 have no defined domains besides their PARP domain, and neither have a known role in the immune response. PARP4, while rapidly evolving as described earlier, has not been reported to have any direct antiviral or proviral activity. PARP16 promotes ER stress responses by ADP-ribosylating IRE1α and PERK (Iwa and Chang 2012), and also ADP-ribosylates Karyopherin β1, indicating a potential role in nuclear transport (Di Paola et al. 2012). However, it also has no known antiviral activities or impact on the innate immune response. Here we focus on PARP10 and PARP11.

**PARP10** PARP10 contains both an RNA recognition motif (RRM), nuclear import and export signals, and two ubiquitin-interacting motifs (UIM) in addition to its catalytic domain [Verheugd et al. 2013] and is highly up-regulated by IFN [Eckei et al. 2017; Grunewald et al. 2019a]. Along with PARP12 and PARP7, it inhibits VEEV replication and blocks protein translation when expressed from a VEEV replicon [Atasheva et al. 2014]. PARP10 also blocks NF-κB signaling and the production of proinflammatory cytokines [Verheugd et al. 2013]. Mechanistically, the UIM of PARP10 interacts with K63-linked ubiquitin chains and NEMO. PARP10 ADP-ribosylates NEMO and prevents its polyubiquitination, which ultimately blocks NF-κB from translocating to the nucleus to activate gene expression [Fig. 1A]. It remains unknown whether this function of PARP10 impacts host–pathogen interactions or whether it functions in other contexts.

**PARP11** PARP11 is the second smallest PARP protein [PARP16 is the smallest], with only a single WWE domain in addition to its ART domain, and is also highly up-regulated by IFN [Grunewald et al. 2019a]. Recently, PARP11 was shown to block IFN signaling by ADP-ribosylating the E3 ubiquitin ligase β-transducin repeat-containing protein (β-TrCP), which lead to the ubiquitination and degradation of the interferon α/β receptor (IFNAR) [Fig. 1B; Guo et al. 2019]. siRNA silencing of PARP11 or treatment with rucaparib, a pan-PARP inhibitor used in advanced ovarian cancer, inhibited the replication of VSV and HSV-1. While normally known to inhibit PARP1/2, at the concentrations of drug used in this study rucaparib appeared to preferentially target PARP11. Interestingly, following infection in vivo, rucaparib enhanced IFN-1 signaling, reduced VSV replication in multiple organs, and led to better outcomes for the mice infected with either VSV or HSV-1. These data indicate that PARP11-specific inhibitors could be a useful means of treating specific viral infections.

In summary, several of the nonenzymatic or mono-ADP-ribosylating PARPs are potent antiviral proteins that are able to inhibit viruses from several different viral families. However, some do contain activities that promote virus replication. While some mechanisms are known, including blocking translation, degrading RNA, and targeting viral or host proteins for ubiquitination and degradation, many mechanisms are still unknown. However, recent reports are making it clear that in many, but not all cases, ADP-ribosylation is tied to protein homeostasis, either through mediating translation or ubiquitination-dependent protein degradation. In addition, several studies have identified multiple points where the innate immune response is modulated by PARPs and ADP-ribosylation [Fig. 1]. The identification of similar and potentially novel processes mediated by PARPs in virus infections will likely be uncovered in the near future.

**Final remarks**

With the advent of new mass spectrometry techniques and improved tools for detecting ADP-ribose, the last decade has seen an explosion in our understanding of how PARPs and ADP-ribose impact not just immunity, but biology in general. This technological development is exponential, which will further facilitate PARP research in the future. PARP inhibitors are being tested in the clinic for chemotherapy, so it is likely that PARP inhibitors or agonists could be useful for treating immune disorders as well. However, developing PARP-specific inhibitors or agonists will be challenging. There is still a long way to go before we fully understand how PARPs function both in cell culture and in vivo to target them for the treatment of infections or immune diseases. Additional PARP-deficient animals and specific inhibitors are needed to gain a better knowledge of how PARPs impact pathogenesis from infection or immune-mediated diseases. While PARPs are structurally and functionally distinct, specificity and off-target effects of PARP inhibitors remain incompletely understood; thus, further characterization of each compound is necessary.

Accumulating clinical and scientific evidence supports a theory that inflammation promotes various global health threats such as myocardial infarction. However, mechanisms of macrophage activation, for instance,
remain obscure. Recent understanding that macrophages are highly heterogeneous has added to the complexity of inflammation. What is the role of each PARP in inflammation via an enzymatic activity-dependent or independent mechanism? What is a specific function of each domain in macrophage activation? Furthermore, additional roles for PARPs in the antiviral response are likely to exist, especially for PARPs that are under strong positive selection pressure, but have yet to be associated with a specific biological activity. In several cases the mechanism used by PARPs to inhibit specific viruses remain unknown. It is also intriguing that several IFN-induced PARPs have been shown to enhance virus replication. Could this be a mechanism by the host to maintain a minimal amount of virus replication in vivo so that the immune system can be appropriately activated? The answers to these and many other questions will be of great interest to PARP researchers, immunologists, and microbiologists as they are likely to uncover unique cellular processes regulated by ADP-ribosylation that could lead to the identification of novel therapeutic targets for infections or immune-mediated diseases.

Acknowledgments

We thank Melody Li for critically reading this manuscript. This work was supported in part by National Institutes of Health grants CoBRE P20 GM113117-02 and K22 AI134993-01 to A.R.F. and R01 HL126901 to M.A., and by the Kowa Company, Ltd. [M.A.].

REFERENCES


Caprara G, Prosperini E, Piccolo V, Sigismondo G, Melacarne A, Cuomo A, Boothby M, Rescigno M, Bonaldi T, Natoli G. 2018. PARP14 controls the nuclear accumulation of a subset of...


and PARP14 cross-regulate macrophage activation via STAT1
ADP-ribosylation. *Nat Commun* 7: 12849. doi:10.1038/ncomms12849

Jankievicius G, Hassler M, Golia B, Rybin V, Zacharias M,

Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu
PD-L1 expression and enhances cancer-associated immuno-


Juszczynska M, Kutok JL, Li C, Mitra J, Aguilar BC, Shipp MA.


Kameoka M, Nukuzuma S, Itaya A, Tanaka Y, Ota K, Inada Y,

Kerns JA, Emerman M, Malik HS. 2008. Positive selection and in-

Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH, Lüscher B. 2008. Substrate-assisted cata-
ylysis by PARP10 limits its activity to mono-ADP-

Koonin EV, Gorbaleyna AE, Purdy MA, Rozanov MN, Reyes GR,
Bradley DW. 1992. Computer-assisted assignment of func-

Kozaki T, Takahama M, Misawa T, Matsuura Y, Akira S, Saitoh T.

Kozaki T, Komoan J, Kanbayashi D, Takahama M, Misawa T,

Krishnamurthy P, Kaplan MH. 2016. STAT6 and PARP family members in the development of T cell-dependent allergic in-

Kunze FA, Hottiger MO. 2019. Regulating immunity via ADP-

of in vivo ADP-ribose acceptor sites by liquid chromatog-

Law LMJ, Razooky BS, Li MMH, You S, Jurado A, Rice CM, Mac-
Donald MR. 2019. ZAP's stress granule localization is corre-

Lee H, Komano J, Saitoh T, Yamaoka S, Kozaki T, Misawa T,

Leung AK. 2014. Poly(ADP-ribose)-: an organizer of cellular archi-


Leung AKL, McPherson RL, Griffin DE. 2018. Macromdomain
ADP-ribohydrolylase and the pathogenesis of infectious dis-


Li C, Debong Y, Jankievicius G, Neyts J, Abele I, Coutard B, Canard B. 2016. Viral macro domains reverse protein ADP-ribo-

Li MM, Lau Z, Zehn P, Aguilar EG, Schneider WM, Bozzaoco L,


Park E, Griffin DE. 2009. The nsP3 macro domain is important for Sindbis virus replication in neurons and neurovirulence in mice. Virology 388: 305–314. doi:10.1016/j.virol.2009.03.031


Fehr et al.
The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions

Anthony R. Fehr, Sasha A. Singh, Catherine M. Kerr, et al.

Genes Dev. published online February 6, 2020
Access the most recent version at doi:10.1101/gad.334425.119

Related Content

<table>
<thead>
<tr>
<th>PARPs and ADP-ribosylation: 60 years on</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. Lee Kraus</td>
</tr>
<tr>
<td>Genes Dev. March, 2020 34: 251-253</td>
</tr>
<tr>
<td>Interplay between compartmentalized NAD+-synthesis and consumption: a focus on the PARP family</td>
</tr>
<tr>
<td>Michael S. Cohen</td>
</tr>
<tr>
<td>Genes Dev. March, 2020 34: 254-262</td>
</tr>
<tr>
<td>(ADP-ribosyl)hydrolases: structure, function, and biology</td>
</tr>
<tr>
<td>Johannes Gregor Matthias Rack, Luca Palazzo and Ivan Ahel</td>
</tr>
<tr>
<td>Genes Dev. March, 2020 34: 263-284</td>
</tr>
<tr>
<td>Nuclear PARPs and genome integrity</td>
</tr>
<tr>
<td>Kameron Azarm and Susan Smith</td>
</tr>
<tr>
<td>Genes Dev. March, 2020 34: 285-301</td>
</tr>
<tr>
<td>PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis</td>
</tr>
<tr>
<td>Dae-Seok Kim, Sridevi Challa, Aarin Jones, et al.</td>
</tr>
<tr>
<td>Genes Dev. March, 2020 34: 302-320</td>
</tr>
<tr>
<td>The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism</td>
</tr>
<tr>
<td>Magdolna Szántó and Peter Bai</td>
</tr>
<tr>
<td>PARP and PARG inhibitors in cancer treatment</td>
</tr>
<tr>
<td>Dea Slade</td>
</tr>
<tr>
<td>Genes Dev. March, 2020 34: 360-394</td>
</tr>
</tbody>
</table>

Published online February 6, 2020 in advance of the full issue.

Creative Commons License

This article, published in Genes Development, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here.